Clinical trials: Breast Cancer, Male
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié
Breast Cancer
Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00182793
- Testing
- trastuzumab, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Lung Cancer
Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning
The goal of this clinical trial is to explore feasibility, acceptability, and effectiveness of end-of-life conversation game "Hello" as a tool to help individuals with breast, lung, and/or genito-urinary cancers treated at Penn…
- Conditions
- Breast Cancer, Lung Cancer, Genito Urinary Cancer
- Trial name
- NCT06028152
- Testing
- End-of-life conversation game called "Hello"
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Milton S. Hershey Medical Center
Breast Cancer
Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00020332
- Testing
- alvocidib, docetaxel
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Prostatic Neoplasms, Breast Neoplasms
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR The goals of this study are to improve adherence to oral chemotherapeutic medications and self-management of symptoms among cancer patients.
- Conditions
- Prostatic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Melanoma
- Trial name
- NCT02043184
- Testing
- Interactive Voice Response (IVR) Reminders
- Where
- 8 sites in United States
- Volunteers
- 322 people
- Sponsor
- Michigan State University
Elderly, Breast Cancer
Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.
The incidence of cancer among older adults is increasing as a result of longer life expectancy. Therapeutic advances have led oncologists to propose new available treatments for these patients, particularly oral therapies…
- Conditions
- Elderly, Breast Cancer, Lung Cancer, Prostate Cancer
- Trial name
- POG (NCT07802847)
- Testing
- Experimental
- Where
- France
- Volunteers
- 794 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Breast Cancer, Renal Cell Carcinoma
Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study)
Everolimus shows a large interpatient variability with fixed dose administration. These very different exposure levels between individuals can result in supratherapeutic or subtherapeutic exposure levels and consequently in over…
- Trial name
- SPOT (NCT02809404)
- Testing
- Everolimus
- Where
- Netherlands
- Volunteers
- 75 people
- Sponsor
- Radboud University Medical Center
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Advanced Glioblastoma, Advanced Colorectal Cancer
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
ONC201 is a new potential drug that kills cancer cells but not normal cells in laboratory studies. This clinical trial will be the first evaluation of ONC201 in humans and will enroll patients with advanced cancer.
- Conditions
- Advanced Glioblastoma, Advanced Colorectal Cancer, Advanced Triple-negative Breast Cancer, Advanced Non-small Cell Lung Cancer
- Trial name
- NCT02038699
- Testing
- ONC201
- Where
- United States
- Sponsor
- Jazz Pharmaceuticals
Breast Cancer, Colorectal Cancer (CRC)
Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study
Summary Reducing sedentary behavior during treatment is important to reduce the risk of future health problems in individuals undergoing cancer treatment.
- Conditions
- Breast Cancer, Colorectal Cancer (CRC), Prostate Cancer, Neoadjuvant Therapy
- Trial name
- RedSedCan (NCT06719206)
- Testing
- Digital self-management program
- Where
- 2 sites in Sweden
- Volunteers
- 210 people
- Sponsor
- Mälardalen University
Metastatic Breast Cancer, Colorectal Cancer
Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer
The Wnt proteins belong to a family of proteins that have been demonstrated to play a role in the formation and dissemination of tumours.
- Conditions
- Metastatic Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT02020291
- Testing
- Foxy-5
- Where
- Denmark
- Volunteers
- 31 people
- Sponsor
- WntResearch AB
Breast Cancer, Prostate Cancer
Tempus Priority Study: A Pan-tumor Observational Study
Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with…
- Conditions
- Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer
- Trial name
- NCT05179824
- Testing
- Observation
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Tempus AI
Breast Cancer, Ovarian Cancer
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
This is a single-center, randomized, single-blinded, three-arm phase Ib study of the folate binding protein vaccines E39 and J65.
- Trial name
- J65 (NCT02019524)
- Testing
- E39 peptide vaccine, E39 vaccine then J65 vaccine, J65 vaccine then E39 vaccine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- COL George Peoples, MD, FACS
Breast Cancer, Testicular Cancer
Knowledge and Attitudes Regarding Healthy Lifestyle and Health Behavior Change in Cancer Patients and Their Partners; A Pilot Study
The investigators will perform a pilot study to gain insight into attitudes, barriers and facilitators for health behavior change in cancer patients and their partners.
- Trial name
- NCT02602041
- Testing
- Literature search and semi-structured interview
- Where
- Netherlands
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Breast Cancer Metastatic, Renal Cell Carcinoma (RCC)
Sapu003 in Advanced mTOR-sensitive Solid Tumors
This is a phase 1b, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics of Sapu003 in combination with Exemestane in in patients with advanced mTOR-sensitive solid tumors (HR+/HER2-negative…
- Conditions
- Breast Cancer Metastatic, Renal Cell Carcinoma (RCC), Neuroendocrine Tumors, Tuberous Sclerosis Complex (TSC)
- Trial name
- NCT07369505
- Testing
- Sapu003, Exemestane 25 MG
- Where
- Australia
- Volunteers
- 27 people
- Sponsor
- SAPU NANO (US) LLC
Male Breast Cancer, Recurrent Breast Cancer
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01153672
- Testing
- vorinostat, laboratory biomarker analysis, biopsy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Washington
HER2-positive Breast Cancer, Male Breast Cancer
Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
This phase I trial studies the side effects and the best dose of Akt inhibitor MK2206 and lapatinib ditosylate in treating patients with solid tumors or breast cancer that has spread to other places in the body.
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT01245205
- Testing
- Akt inhibitor MK2206, lapatinib ditosylate, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Cancer
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
RATIONALE: White blood cells from donors who have been exposed to cytomegalovirus may be able to help prevent this infection from occurring in patients who are undergoing bone marrow or peripheral stem cell transplantation.
- Trial name
- NCT00002673
- Testing
- infection prophylaxis and management
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00002854
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.